Current reimbursement models in general do not accommodate many of the unique factors common among gene and cell therapies. In this second article of a three-part series, CRA’s Walter Colasante, Pascale Diesel, and Lev Gerlovin discuss the challenges to demonstrating value and addressing affordability and discuss options for payment models.
The authors wish to acknowledge the contributions of Stephanie Donahue and Michael Krepps to this article.
Click here to read the article.
The 3 business models that will attract buyers to my high-cost medical device
The global medical devices market is projected to grow at 4.4% CAGR until 2025. But large medical devices with high initial procurement costs are experiencing...